Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) EBT Margin (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed EBT Margin for 16 consecutive years, with 206.44% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 6499356.0% to 206.44% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 416.95% through Dec 2025, up 3411162.0% year-over-year, with the annual reading at 416.69% for FY2025, 3411188.0% up from the prior year.
  • EBT Margin hit 206.44% in Q4 2025 for Guided Therapeutics, up from 1236.67% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 357.89% in Q3 2021 to a low of 65200.0% in Q4 2024.
  • Historically, EBT Margin has averaged 14300.47% across 5 years, with a median of 3744.32% in 2023.
  • Biggest five-year swings in EBT Margin: crashed -6399375bps in 2024 and later surged 6499356bps in 2025.
  • Year by year, EBT Margin stood at 740.0% in 2021, then plummeted by -4864bps to 36733.33% in 2022, then surged by 97bps to 1206.25% in 2023, then tumbled by -5305bps to 65200.0% in 2024, then soared by 100bps to 206.44% in 2025.
  • Business Quant data shows EBT Margin for GTHP at 206.44% in Q4 2025, 1236.67% in Q3 2025, and 693.16% in Q2 2025.